Medical School MD-PhD Program

Research products

All my research products

Selected research products

Malatesta S, Vigiano Benedetti V, Salviati E, Illi B, Manni I, Middonti E, Rampioni Vinciguerra GL, Licursi V, Troilo F, Colotti G, Cipolla L, Sabbioneda S, Perfetto L, Piaggio G, Bussolino F, Di Nicolantonio F, Campiglia P, Sommella EM, Mori M, Cencioni C, Spallotta F. (2026) alpha-ketoglutarate/succinate ratio imbalance impairs thymine DNA glycosylase function and base excision repair process increasing susceptibility to pancreatic cancer. Cell death & disease 17(1) [DOI  PMID]

Vitiello PP, Rousseau B, Chila R, Battuello P, Amodio V, Battaglieri V, Grasso G, Scardellato S, Anselmo A, Clemente F, Rospo G, Lamba S, Bartolini A, Pisati F, Tripodo C, Congiusta N, Russo M, Crisafulli G, Di Nicolantonio F, Germano G, Diaz LA Jr, Bardelli A. (2025) Cisplatin and temozolomide combinatorial treatment triggers hypermutability and immune surveillance in experimental cancer models. Cancer cell 43(7) 1296-1312.e7 [DOI  PMID]

Aroldi F, Elez E, Andre T, Perkins G, Prenen H, Popovici V, Gallagher P, Houlden J, Collins L, Roberts C, Rolfo C, Di Nicolantonio F, Grayson M, Boyd R, Bettens K, Delfavero J, Coyle V, Lawler M, Khawaja H, Laurent-Puig P, Salto-Tellez M, Maughan TS, Tabernero J, Adams R, Jones R, Hennessy BT, Bardelli A, Peeters M, Middleton MR, Wilson RH, Van Schaeybroeck S. (2025) A Phase Ia/b study of MEK1/2 inhibitor binimetinib with MET inhibitor crizotinib in patients with RAS mutant advanced colorectal cancer (MErCuRIC). BMC cancer 25(1) 658 [DOI  PMID]

Gallagher P, Rolfo C, Elez E, Taieb J, Houlden J, Collins L, Roberts C, Andre T, Lawler M, Di Nicolantonio F, Grayson M, Boyd R, Popovici V, Bardelli A, Carson R, Khawaja H, Laurent-Puig P, Salto-Tellez M, Hennessy BT, Maughan TS, Tabernero J, Adams R, Jones R, Peeters M, Middleton MR, Wilson RH, Van Schaeybroeck S. (2025) A phase Ia study of the MEK1/2 inhibitor PD-0325901 with the c-MET inhibitor crizotinib in patients with advanced solid cancers. BJC reports 3(1) 17 [DOI  PMID]

Macagno M, Pessei V, Congiusta N, Lazzari L, Bellomo SE, Idrees F, Cavaliere A, Pietrantonio F, Raimondi A, Gusmaroli E, Zampino MG, Gervaso L, Ciardiello D, Mondello G, Santoro A, Personeni N, Bonoldi E, Aquilano MC, Valtorta E, Siena S, Sartore-Bianchi A, Amatu A, Bonazzina EF, Bencardino KB, Serini G, Marsoni S, Barault L, Di Nicolantonio F, Maione F. (2024) A Comparative Study of Methyl-BEAMing and Droplet Digital PCR for MGMT Gene Promoter Hypermethylation Detection. Diagnostics (Basel, Switzerland) 14(22) [DOI  PMID]

Corti G, Buzo K, Berrino E, Miotto M, Aquilano MC, Lentini M, Bellomo SE, Lorenzato A, Bartolini A, Mauri G, Lazzari L, Russo M, Di Nicolantonio F, Siena S, Marsoni S, Marchio C, Bardelli A, Arena S. (2024) Prediction of homologous recombination deficiency identifies colorectal tumors sensitive to PARP inhibition. NPJ precision oncology 8(1) 231 [DOI  PMID]

Pessei V, Macagno M, Mariella E, Congiusta N, Battaglieri V, Battuello P, Viviani M, Gionfriddo G, Lamba S, Lorenzato A, Oddo D, Idrees F, Cavaliere A, Bartolini A, Guarrera S, Linnebacher M, Monteonofrio L, Cardone L, Milella M, Bertotti A, Soddu S, Grassi E, Crisafulli G, Bardelli A, Barault L, Di Nicolantonio F. (2024) DNA demethylation triggers cell free DNA release in colorectal cancer cells. Genome medicine 16(1) 118 [DOI  PMID]

Mirandola A, Kudriavtsev A, Cofre Munoz CI, Navarro RC, Macagno M, Daoud S, Sanchez C, Pastor B, Pisareva E, Marin MS, Ruiz JG, Piris A, Rodriguez AG, Gonzalez NS, Vivancos A, Quara V, Mellano A, Borghi F, Corti G, Marchio C, Sapino A, Bartolini A, Crisafulli G, Bardelli A, Di Maio M, Lossaint G, Frayssinoux F, Crapez E, Ychou M, Soler RS, Fenocchio E, Fernandez Calotti PX, Mazard T, Vivas CS, Elez E, Di Nicolantonio F, Thierry AR. (2024) Post-surgery sequelae unrelated to disease progression and chemotherapy revealed in follow-up of patients with stage III colon cancer. EBioMedicine 108 105352 [DOI  PMID]

Battuello P, Corti G, Bartolini A, Lorenzato A, Sogari A, Russo M, Di Nicolantonio F, Bardelli A, Crisafulli G. (2024) Mutational signatures of colorectal cancers according to distinct computational workflows. Briefings in bioinformatics 25(4) [DOI  PMID]

Mariella E, Grasso G, Miotto M, Buzo K, Reilly NM, Andrei P, Vitiello PP, Crisafulli G, Arena S, Rospo G, Corti G, Lorenzato A, Cancelliere C, Barault L, Gionfriddo G, Linnebacher M, Russo M, Di Nicolantonio F, Bardelli A. (2024) Transcriptome-wide gene expression outlier analysis pinpoints therapeutic vulnerabilities in colorectal cancer. Molecular oncology 18(6) 1460-1485 [DOI  PMID]

Maione F, Oddo D, Galvagno F, Falcomata C, Pandini M, Macagno M, Pessei V, Barault L, Gigliotti C, Mira A, Corti G, Lamba S, Riganti C, Castella B, Massaia M, Rad R, Saur D, Bardelli A, Di Nicolantonio F. (2024) Preclinical efficacy of carfilzomib in BRAF-mutant colorectal cancer models. Molecular oncology 18(6) 1552-1570 [DOI  PMID]

Rospo G, Chila R, Matafora V, Basso V, Lamba S, Bartolini A, Bachi A, Di Nicolantonio F, Mondino A, Germano G, Bardelli A. (2024) Non-canonical antigens are the largest fraction of peptides presented by MHC class I in mismatch repair deficient murine colorectal cancer. Genome medicine 16(1) 15 [DOI  PMID]

Sogari A, Rovera E, Grasso G, Mariella E, Reilly NM, Lamba S, Mauri G, Durinikova E, Vitiello PP, Lorenzato A, Avolio M, Piumatti E, Bonoldi E, Aquilano MC, Arena S, Sartore-Bianchi A, Siena S, Trusolino L, Donalisio M, Russo M, Di Nicolantonio F, Lembo D, Bardelli A. (2024) Tolerance to colibactin correlates with homologous recombination proficiency and resistance to irinotecan in colorectal cancer cells. Cell reports. Medicine 5(2) 101376 [DOI  PMID]

Patelli G, Mauri G, Tosi F, Amatu A, Bencardino K, Bonazzina E, Pizzutilo EG, Villa F, Calvanese G, Agostara AG, Stabile S, Ghezzi S, Crisafulli G, Di Nicolantonio F, Marsoni S, Bardelli A, Siena S, Sartore-Bianchi A. (2023) Circulating Tumor DNA to Drive Treatment in Metastatic Colorectal Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 29(22) 4530-4539 [DOI  PMID]

Comunanza V, Gigliotti C, Lamba S, Doronzo G, Vallariello E, Martin V, Isella C, Medico E, Bardelli A, Sangiolo D, Di Nicolantonio F, Bussolino F. (2023) Dual VEGFA/BRAF targeting boosts PD-1 blockade in melanoma through GM-CSF-mediated infiltration of M1 macrophages. Molecular oncology 17(8) 1474-1491 [DOI  PMID]

Bersani F, Picca F, Morena D, Righi L, Napoli F, Russo M, Oddo D, Rospo G, Negrino C, Castella B, Volante M, Listi A, Zambelli V, Benso F, Tabbo F, Bironzo P, Monteleone E, Poli V, Pietrantonio F, Di Nicolantonio F, Bardelli A, Ponzetto C, Novello S, Scagliotti GV, Taulli R. (2023) Exploring circular MET RNA as a potential biomarker in tumors exhibiting high MET activity. Journal of experimental & clinical cancer research : CR 42(1) 120 [DOI  PMID]

Nicolazzo C, Magri V, Marino L, Belardinilli F, Di Nicolantonio F, De Renzi G, Caponnetto S, De Meo M, Giannini G, Santini D, Cortesi E, Gazzaniga P. (2023) Genomic landscape and survival analysis of ctDNA "neo-RAS wild-type" patients with originally RAS mutant metastatic colorectal cancer. Frontiers in oncology 13 1160673 [DOI  PMID]

Di Nicolantonio F, Bardelli A. (2023) Precision oncology for KRAS(G12C)-mutant colorectal cancer. Nature reviews. Clinical oncology 20(6) 355-356 [DOI  PMID]

Amodio V, Lamba S, Chila R, Cattaneo CM, Mussolin B, Corti G, Rospo G, Berrino E, Tripodo C, Pisati F, Bartolini A, Aquilano MC, Marsoni S, Mauri G, Marchio C, Abrignani S, Di Nicolantonio F, Germano G, Bardelli A. (2023) Genetic and pharmacological modulation of DNA mismatch repair heterogeneous tumors promotes immune surveillance. Cancer cell 41(1) 196-209.e5 [DOI  PMID]

Marini E, Marino M, Gionfriddo G, Maione F, Pandini M, Oddo D, Giorgis M, Rolando B, Blua F, Gastaldi S, Marchio S, Kovachka S, Spyrakis F, Gianquinto E, Di Nicolantonio F, Bertinaria M. (2022) Investigation into the Use of Encorafenib to Develop Potential PROTACs Directed against BRAF(V600E) Protein. Molecules (Basel, Switzerland) 27(23) [DOI  PMID]

Lawler M, Davies L, Oberst S, Oliver K, Eggermont A, Schmutz A, La Vecchia C, Allemani C, Lievens Y, Naredi P, Cufer T, Aggarwal A, Aapro M, Apostolidis K, Baird AM, Cardoso F, Charalambous A, Coleman MP, Costa A, Crul M, Degi CL, Di Nicolantonio F, Erdem S, Geanta M, Geissler J, Jassem J, Jagielska B, Jonsson B, Kelly D, Kelm O, Kolarova T, Kutluk T, Lewison G, Meunier F, Pelouchova J, Philip T, Price R, Rau B, Rubio IT, Selby P, Juznic Sotlar M, Spurrier-Bernard G, van Hoeve JC, Vrdoljak E, Westerhuis W, Wojciechowska U, Sullivan R. (2023) European Groundshot-addressing Europe's cancer research challenges: a Lancet Oncology Commission. The Lancet. Oncology 24(1) e11-e56 [DOI  PMID]

Khawaja H, Briggs R, Latimer CH, Rassel M, Griffin D, Hanson L, Bardelli A, Di Nicolantonio F, McDade SS, Scott CJ, Lambe S, Maurya M, Lindner AU, Prehn JHM, Sousa J, Winnington C, LaBonte MJ, Ross S, Van Schaeybroeck S. (2023) Bcl-xL Is a Key Mediator of Apoptosis Following KRASG12C Inhibition in KRASG12C-mutant Colorectal Cancer. Molecular cancer therapeutics 22(1) 135-149 [DOI  PMID]

Pergolizzi M, Bizzozero L, Maione F, Maldi E, Isella C, Macagno M, Mariella E, Bardelli A, Medico E, Marchio C, Serini G, Di Nicolantonio F, Bussolino F, Arese M. (2022) The neuronal protein Neuroligin 1 promotes colorectal cancer progression by modulating the APC/beta-catenin pathway. Journal of experimental & clinical cancer research : CR 41(1) 266 [DOI  PMID]

Durinikova E, Reilly NM, Buzo K, Mariella E, Chila R, Lorenzato A, Dias JML, Grasso G, Pisati F, Lamba S, Corti G, Degasperi A, Cancelliere C, Mauri G, Andrei P, Linnebacher M, Marsoni S, Siena S, Sartore-Bianchi A, Nik-Zainal S, Di Nicolantonio F, Bardelli A, Arena S. (2022) Targeting the DNA Damage Response Pathways and Replication Stress in Colorectal Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 28(17) 3874-3889 [DOI  PMID]

Russo M, Pompei S, Sogari A, Corigliano M, Crisafulli G, Puliafito A, Lamba S, Erriquez J, Bertotti A, Gherardi M, Di Nicolantonio F, Bardelli A, Cosentino Lagomarsino M. (2022) A modified fluctuation-test framework characterizes the population dynamics and mutation rate of colorectal cancer persister cells. Nature genetics 54(7) 976-984 [DOI  PMID]

Crisafulli G, Sartore-Bianchi A, Lazzari L, Pietrantonio F, Amatu A, Macagno M, Barault L, Cassingena A, Bartolini A, Luraghi P, Mauri G, Battuello P, Personeni N, Zampino MG, Pessei V, Vitiello PP, Tosi F, Idotta L, Morano F, Valtorta E, Bonoldi E, Germano G, Di Nicolantonio F, Marsoni S, Siena S, Bardelli A. (2022) Temozolomide Treatment Alters Mismatch Repair and Boosts Mutational Burden in Tumor and Blood of Colorectal Cancer Patients. Cancer discovery 12(7) 1656-1675 [DOI  PMID]

Nicolazzo C, Belardinilli F, Vestri A, Magri V, De Renzi G, De Meo M, Caponnetto S, Di Nicolantonio F, Cortesi E, Giannini G, Gazzaniga P. (2022) RAS Mutation Conversion in Bevacizumab-Treated Metastatic Colorectal Cancer Patients: A Liquid Biopsy Based Study. Cancers 14(3) [DOI  PMID]

Bianchi F, Dama E, Di Nicolantonio F, Baldassarre G, Guerriero I, Torchiaro E, Bruno A, Blandino G, Allavena P, Chiarugi P, Sozzi G, D'Incalci M, Normanno N. (2021) Corrigendum to 'COVID-19 epidemic strongly affected cancer research in Italy: a survey of the Italian Cancer Society (SIC)': [ESMO Open Volume 6, Issue 3, June 2021, 100165]. ESMO open 6(4) 100243 [DOI  PMID]

Anobile DP, Bironzo P, Picca F, Lingua MF, Morena D, Righi L, Napoli F, Papotti MG, Pittaro A, Di Nicolantonio F, Gigliotti C, Bussolino F, Comunanza V, Guerrera F, Sandri A, Leo F, Libener R, Aviles P, Novello S, Taulli R, Scagliotti GV, Riganti C. (2021) Evaluation of the Preclinical Efficacy of Lurbinectedin in Malignant Pleural Mesothelioma. Cancers 13(10) [DOI  PMID]

Bianchi F, Dama E, Di Nicolantonio F, Baldassarre G, Guerriero I, Torchiaro E, Bruno A, Blandino G, Allavena P, Chiarugi P, Sozzi G, D'Incalci M, Normanno N. (2021) COVID-19 epidemic strongly affected cancer research in Italy: a survey of the Italian Cancer Society (SIC). ESMO open 6(3) 100165 [DOI  PMID]

Di Nicolantonio F, Vitiello PP, Marsoni S, Siena S, Tabernero J, Trusolino L, Bernards R, Bardelli A. (2021) Precision oncology in metastatic colorectal cancer - from biology to medicine. Nature reviews. Clinical oncology 18(8) 506-525 [DOI  PMID]

Picco G, Cattaneo CM, van Vliet EJ, Crisafulli G, Rospo G, Consonni S, Vieira SF, Rodriguez IS, Cancelliere C, Banerjee R, Schipper LJ, Oddo D, Dijkstra KK, Cinatl J, Michaelis M, Yang F, Di Nicolantonio F, Sartore-Bianchi A, Siena S, Arena S, Voest EE, Bardelli A, Garnett MJ. (2021) Werner Helicase Is a Synthetic-Lethal Vulnerability in Mismatch Repair-Deficient Colorectal Cancer Refractory to Targeted Therapies, Chemotherapy, and Immunotherapy. Cancer discovery 11(8) 1923-1937 [DOI  PMID]

Nicolazzo C, Barault L, Caponnetto S, De Renzi G, Belardinilli F, Bottillo I, Bargiacchi S, Macagno M, Grammatico P, Giannini G, Cortesi E, Di Nicolantonio F, Gazzaniga P. (2021) True conversions from RAS mutant to RAS wild-type in circulating tumor DNA from metastatic colorectal cancer patients as assessed by methylation and mutational signature. Cancer letters 507 89-96 [DOI  PMID]

Germano G, Lu S, Rospo G, Lamba S, Rousseau B, Fanelli S, Stenech D, Le DT, Hays J, Totaro MG, Amodio V, Chila R, Mondino A, Diaz LA Jr, Di Nicolantonio F, Bardelli A. (2021) CD4 T Cell-Dependent Rejection of Beta-2 Microglobulin Null Mismatch Repair-Deficient Tumors. Cancer discovery 11(7) 1844-1859 [DOI  PMID]

Nicolazzo C, Barault L, Caponnetto S, Macagno M, De Renzi G, Gradilone A, Belardinilli F, Cortesi E, Di Nicolantonio F, Gazzaniga P. (2020) Circulating Methylated DNA to Monitor the Dynamics of RAS Mutation Clearance in Plasma from Metastatic Colorectal Cancer Patients. Cancers 12(12) [DOI  PMID]

Khawaja H, Campbell A, Roberts JZ, Javadi A, O'Reilly P, McArt D, Allen WL, Majkut J, Rehm M, Bardelli A, Di Nicolantonio F, Scott CJ, Kennedy R, Vitale N, Harrison T, Sansom OJ, Longley DB, Evergren E, Van Schaeybroeck S. (2020) RALB GTPase: a critical regulator of DR5 expression and TRAIL sensitivity in KRAS mutant colorectal cancer. Cell death & disease 11(10) 930 [DOI  PMID]

Godel M, Morena D, Ananthanarayanan P, Buondonno I, Ferrero G, Hattinger CM, Di Nicolantonio F, Serra M, Taulli R, Cordero F, Riganti C, Kopecka J. (2020) Small Nucleolar RNAs Determine Resistance to Doxorubicin in Human Osteosarcoma. International journal of molecular sciences 21(12) [DOI  PMID]

Amodio V, Yaeger R, Arcella P, Cancelliere C, Lamba S, Lorenzato A, Arena S, Montone M, Mussolin B, Bian Y, Whaley A, Pinnelli M, Murciano-Goroff YR, Vakiani E, Valeri N, Liao WL, Bhalkikar A, Thyparambil S, Zhao HY, de Stanchina E, Marsoni S, Siena S, Bertotti A, Trusolino L, Li BT, Rosen N, Di Nicolantonio F, Bardelli A, Misale S. (2020) EGFR Blockade Reverts Resistance to KRAS(G12C) Inhibition in Colorectal Cancer. Cancer discovery 10(8) 1129-1139 [DOI  PMID]

Lorenzato A, Magri A, Matafora V, Audrito V, Arcella P, Lazzari L, Montone M, Lamba S, Deaglio S, Siena S, Bertotti A, Trusolino L, Bachi A, Di Nicolantonio F, Bardelli A, Arena S. (2020) Vitamin C Restricts the Emergence of Acquired Resistance to EGFR-Targeted Therapies in Colorectal Cancer. Cancers 12(3) [DOI  PMID]

Crisafulli G, Mussolin B, Cassingena A, Montone M, Bartolini A, Barault L, Martinetti A, Morano F, Pietrantonio F, Sartore-Bianchi A, Siena S, Di Nicolantonio F, Marsoni S, Bardelli A, Siravegna G. (2019) Whole exome sequencing analysis of urine trans-renal tumour DNA in metastatic colorectal cancer patients. ESMO open 4(6) [DOI  PMID]

Magri A, Germano G, Lorenzato A, Lamba S, Chila R, Montone M, Amodio V, Ceruti T, Sassi F, Arena S, Abrignani S, D'Incalci M, Zucchetti M, Di Nicolantonio F, Bardelli A. (2020) High-dose vitamin C enhances cancer immunotherapy. Science translational medicine 12(532) [DOI  PMID]

Arena S, Corti G, Durinikova E, Montone M, Reilly NM, Russo M, Lorenzato A, Arcella P, Lazzari L, Rospo G, Pagani M, Cancelliere C, Negrino C, Isella C, Bartolini A, Cassingena A, Amatu A, Mauri G, Sartore-Bianchi A, Mittica G, Medico E, Marsoni S, Linnebacher M, Abrignani S, Siena S, Di Nicolantonio F, Bardelli A. (2020) A Subset of Colorectal Cancers with Cross-Sensitivity to Olaparib and Oxaliplatin. Clinical cancer research : an official journal of the American Association for Cancer Research 26(6) 1372-1384 [DOI  PMID]

Pietrantonio F, Lobefaro R, Antista M, Lonardi S, Raimondi A, Morano F, Mosconi S, Rimassa L, Murgioni S, Sartore-Bianchi A, Tomasello G, Longarini R, Farina G, Petrelli F, Gori S, Randon G, Corallo S, Pagani F, Guarini V, Palermo F, Martinetti A, Macagno M, Barault L, Perrone F, Tamborini E, Milione M, Di Nicolantonio F, Di Maio M, Fuca G, Di Bartolomeo M, de Braud F. (2020) Capecitabine and Temozolomide versus FOLFIRI in RAS-Mutated, MGMT-Methylated Metastatic Colorectal Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 26(5) 1017-1024 [DOI  PMID]

Russo M, Crisafulli G, Sogari A, Reilly NM, Arena S, Lamba S, Bartolini A, Amodio V, Magri A, Novara L, Sarotto I, Nagel ZD, Piett CG, Amatu A, Sartore-Bianchi A, Siena S, Bertotti A, Trusolino L, Corigliano M, Gherardi M, Lagomarsino MC, Di Nicolantonio F, Bardelli A. (2019) Adaptive mutability of colorectal cancers in response to targeted therapies. Science (New York, N.Y.) 366(6472) 1473-1480 [DOI  PMID]

Lazzari L, Corti G, Picco G, Isella C, Montone M, Arcella P, Durinikova E, Zanella ER, Novara L, Barbosa F, Cassingena A, Cancelliere C, Medico E, Sartore-Bianchi A, Siena S, Garnett MJ, Bertotti A, Trusolino L, Di Nicolantonio F, Linnebacher M, Bardelli A, Arena S. (2019) Patient-Derived Xenografts and Matched Cell Lines Identify Pharmacogenomic Vulnerabilities in Colorectal Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 25(20) 6243-6259 [DOI  PMID]

Amatu A, Schirripa M, Tosi F, Lonardi S, Bencardino K, Bonazzina E, Palmeri L, Patane DA, Pizzutilo EG, Mussolin B, Bergamo F, Alberti G, Intini R, Procaccio L, Arese M, Marsoni S, Nichelatti M, Zagonel V, Siena S, Bardelli A, Loupakis F, Di Nicolantonio F, Sartore-Bianchi A, Barault L. (2019) High Circulating Methylated DNA Is a Negative Predictive and Prognostic Marker in Metastatic Colorectal Cancer Patients Treated With Regorafenib. Frontiers in oncology 9 622 [DOI  PMID]

Rospo G, Lorenzato A, Amirouchene-Angelozzi N, Magri A, Cancelliere C, Corti G, Negrino C, Amodio V, Montone M, Bartolini A, Barault L, Novara L, Isella C, Medico E, Bertotti A, Trusolino L, Germano G, Di Nicolantonio F, Bardelli A. (2019) Evolving neoantigen profiles in colorectal cancers with DNA repair defects. Genome medicine 11(1) 42 [DOI  PMID]

Corti G, Bartolini A, Crisafulli G, Novara L, Rospo G, Montone M, Negrino C, Mussolin B, Buscarino M, Isella C, Barault L, Siravegna G, Siena S, Marsoni S, Di Nicolantonio F, Medico E, Bardelli A. (2019) A Genomic Analysis Workflow for Colorectal Cancer Precision Oncology. Clinical colorectal cancer 18(2) 91-101.e3 [DOI  PMID]

Reilly NM, Novara L, Di Nicolantonio F, Bardelli A. (2019) Exploiting DNA repair defects in colorectal cancer. Molecular oncology 13(4) 681-700 [DOI  PMID]

Schwartz S, Szeto C, Tian Y, Cecchi F, Corallo S, Calegari MA, Di Bartolomeo M, Morano F, Raimondi A, Fuca G, Martinetti A, De Pascalis I, Martini M, Belfiore A, Milione M, Orlandi A, Barault L, Barone C, de Braud F, Di Nicolantonio F, Benz S, Hembrough T, Pietrantonio F. (2019) Refining the selection of patients with metastatic colorectal cancer for treatment with temozolomide using proteomic analysis of O6-methylguanine-DNA-methyltransferase. European journal of cancer (Oxford, England : 1990) 107 164-174 [DOI  PMID]

Siravegna G, Lazzari L, Crisafulli G, Sartore-Bianchi A, Mussolin B, Cassingena A, Martino C, Lanman RB, Nagy RJ, Fairclough S, Rospo G, Corti G, Bartolini A, Arcella P, Montone M, Lodi F, Lorenzato A, Vanzati A, Valtorta E, Cappello G, Bertotti A, Lonardi S, Zagonel V, Leone F, Russo M, Balsamo A, Truini M, Di Nicolantonio F, Amatu A, Bonazzina E, Ghezzi S, Regge D, Vanzulli A, Trusolino L, Siena S, Marsoni S, Bardelli A. (2018) Radiologic and Genomic Evolution of Individual Metastases during HER2 Blockade in Colorectal Cancer. Cancer cell 34(1) 148-162.e7 [DOI  PMID]

Rizzolio S, Cagnoni G, Battistini C, Bonelli S, Isella C, Van Ginderachter JA, Bernards R, Di Nicolantonio F, Giordano S, Tamagnone L. (2018) Neuropilin-1 upregulation elicits adaptive resistance to oncogene-targeted therapies. The Journal of clinical investigation 128(9) 3976-3990 [DOI  PMID]

Russo M, Lamba S, Lorenzato A, Sogari A, Corti G, Rospo G, Mussolin B, Montone M, Lazzari L, Arena S, Oddo D, Linnebacher M, Sartore-Bianchi A, Pietrantonio F, Siena S, Di Nicolantonio F, Bardelli A. (2018) Reliance upon ancestral mutations is maintained in colorectal cancers that heterogeneously evolve during targeted therapies. Nature communications 9(1) 2287 [DOI  PMID]

Morano F, Corallo S, Niger M, Barault L, Milione M, Berenato R, Moretto R, Randon G, Antista M, Belfiore A, Raimondi A, Nichetti F, Martinetti A, Battaglia L, Perrone F, Pruneri G, Falcone A, Di Bartolomeo M, de Braud F, Di Nicolantonio F, Cremolini C, Pietrantonio F. (2018) Temozolomide and irinotecan (TEMIRI regimen) as salvage treatment of irinotecan-sensitive advanced colorectal cancer patients bearing MGMT methylation. Annals of oncology : official journal of the European Society for Medical Oncology 29(8) 1800-1806 [DOI  PMID]

Dunne PD, Coleman HG, Bankhead P, Alderdice M, Gray RT, McQuaid S, Bingham V, Loughrey MB, James JA, McCorry AMB, Gilmore A, Holohan C, Klingbiel D, Tejpar S, Johnston PG, McArt DG, Di Nicolantonio F, Longley DB, Lawler M. (2018) Bcl-xL as a poor prognostic biomarker and predictor of response to adjuvant chemotherapy specifically in BRAF-mutant stage II and III colon cancer. Oncotarget 9(17) 13834-13847 [DOI  PMID]

Fadda A, Gentilini D, Moi L, Barault L, Leoni VP, Sulas P, Zorcolo L, Restivo A, Cabras F, Fortunato F, Zavattari C, Varesco L, Gismondi V, De Miglio MR, Scanu AM, Colombi F, Lombardi P, Sarotto I, Loi E, Leone F, Giordano S, Di Nicolantonio F, Columbano A, Zavattari P. (2018) Colorectal cancer early methylation alterations affect the crosstalk between cell and surrounding environment, tracing a biomarker signature specific for this tumor. International journal of cancer 143(4) 907-920 [DOI  PMID]

Pietrantonio F, Di Nicolantonio F, Schrock AB, Lee J, Morano F, Fuca G, Nikolinakos P, Drilon A, Hechtman JF, Christiansen J, Gowen K, Frampton GM, Gasparini P, Rossini D, Gigliotti C, Kim ST, Prisciandaro M, Hodgson J, Zaniboni A, Chiu VK, Milione M, Patel R, Miller V, Bardelli A, Novara L, Wang L, Pupa SM, Sozzi G, Ross J, Di Bartolomeo M, Bertotti A, Ali S, Trusolino L, Falcone A, de Braud F, Cremolini C. (2018) RET fusions in a small subset of advanced colorectal cancers at risk of being neglected. Annals of oncology : official journal of the European Society for Medical Oncology 29(6) 1394-1401 [DOI  PMID]

Riganti C, Lingua MF, Salaroglio IC, Falcomata C, Righi L, Morena D, Picca F, Oddo D, Kopecka J, Pradotto M, Libener R, Orecchia S, Bironzo P, Comunanza V, Bussolino F, Novello S, Scagliotti GV, Di Nicolantonio F, Taulli R. (2018) Bromodomain inhibition exerts its therapeutic potential in malignant pleural mesothelioma by promoting immunogenic cell death and changing the tumor immune-environment. Oncoimmunology 7(3) e1398874 [DOI  PMID]

Pietrantonio F, Di Nicolantonio F, Schrock AB, Lee J, Tejpar S, Sartore-Bianchi A, Hechtman JF, Christiansen J, Novara L, Tebbutt N, Fuca G, Antoniotti C, Kim ST, Murphy D, Berenato R, Morano F, Sun J, Min B, Stephens PJ, Chen M, Lazzari L, Miller VA, Shoemaker R, Amatu A, Milione M, Ross JS, Siena S, Bardelli A, Ali SM, Falcone A, de Braud F, Cremolini C. (2017) ALK, ROS1, and NTRK Rearrangements in Metastatic Colorectal Cancer. Journal of the National Cancer Institute 109(12) [DOI  PMID]

Germano G, Mauri G, Siravegna G, Dive C, Pierce J, Di Nicolantonio F, D'Incalci M, Bardelli A, Siena S, Sartore-Bianchi A. (2018) Parallel Evaluation of Circulating Tumor DNA and Circulating Tumor Cells in Metastatic Colorectal Cancer. Clinical colorectal cancer 17(1) 80-83 [DOI  PMID]

Germano G, Lamba S, Rospo G, Barault L, Magri A, Maione F, Russo M, Crisafulli G, Bartolini A, Lerda G, Siravegna G, Mussolin B, Frapolli R, Montone M, Morano F, de Braud F, Amirouchene-Angelozzi N, Marsoni S, D'Incalci M, Orlandi A, Giraudo E, Sartore-Bianchi A, Siena S, Pietrantonio F, Di Nicolantonio F, Bardelli A. (2017) Inactivation of DNA repair triggers neoantigen generation and impairs tumour growth. Nature 552(7683) 116-120 [DOI  PMID]

Carbone C, Piro G, Gaianigo N, Ligorio F, Santoro R, Merz V, Simionato F, Zecchetto C, Falco G, Conti G, Kamga PT, Krampera M, Di Nicolantonio F, De Franceschi L, Scarpa A, Tortora G, Melisi D. (2018) Adipocytes sustain pancreatic cancer progression through a non-canonical WNT paracrine network inducing ROR2 nuclear shuttling. International journal of obesity (2005) 42(3) 334-343 [DOI  PMID]

Barault L, Amatu A, Siravegna G, Ponzetti A, Moran S, Cassingena A, Mussolin B, Falcomata C, Binder AM, Cristiano C, Oddo D, Guarrera S, Cancelliere C, Bustreo S, Bencardino K, Maden S, Vanzati A, Zavattari P, Matullo G, Truini M, Grady WM, Racca P, Michels KB, Siena S, Esteller M, Bardelli A, Sartore-Bianchi A, Di Nicolantonio F. (2018) Discovery of methylated circulating DNA biomarkers for comprehensive non-invasive monitoring of treatment response in metastatic colorectal cancer. Gut 67(11) 1995-2005 [DOI  PMID]

Oddo D, Siravegna G, Gloghini A, Vernieri C, Mussolin B, Morano F, Crisafulli G, Berenato R, Corti G, Volpi CC, Buscarino M, Niger M, Dunne PD, Rospo G, Valtorta E, Bartolini A, Fuca G, Lamba S, Martinetti A, Di Bartolomeo M, de Braud F, Bardelli A, Pietrantonio F, Di Nicolantonio F. (2017) Emergence of MET hyper-amplification at progression to MET and BRAF inhibition in colorectal cancer. British journal of cancer 117(3) 347-352 [DOI  PMID]

Siravegna G, Sartore-Bianchi A, Mussolin B, Cassingena A, Amatu A, Novara L, Buscarino M, Corti G, Crisafulli G, Bartolini A, Tosi F, Erlander M, Di Nicolantonio F, Siena S, Bardelli A. (2017) Tracking a CAD-ALK gene rearrangement in urine and blood of a colorectal cancer patient treated with an ALK inhibitor. Annals of oncology : official journal of the European Society for Medical Oncology 28(6) 1302-1308 [DOI  PMID]

Carbone C, Piro G, Simionato F, Ligorio F, Cremolini C, Loupakis F, Ali G, Rossini D, Merz V, Santoro R, Zecchetto C, Zanotto M, Di Nicolantonio F, Bardelli A, Fontanini G, Tortora G, Melisi D. (2017) Homeobox B9 Mediates Resistance to Anti-VEGF Therapy in Colorectal Cancer Patients. Clinical cancer research : an official journal of the American Association for Cancer Research 23(15) 4312-4322 [DOI  PMID]

Fujii T, Barzi A, Sartore-Bianchi A, Cassingena A, Siravegna G, Karp DD, Piha-Paul SA, Subbiah V, Tsimberidou AM, Huang HJ, Veronese S, Di Nicolantonio F, Pingle S, Vibat CRT, Hancock S, Berz D, Melnikova VO, Erlander MG, Luthra R, Kopetz ES, Meric-Bernstam F, Siena S, Lenz HJ, Bardelli A, Janku F. (2017) Mutation-Enrichment Next-Generation Sequencing for Quantitative Detection of KRAS Mutations in Urine Cell-Free DNA from Patients with Advanced Cancers. Clinical cancer research : an official journal of the American Association for Cancer Research 23(14) 3657-3666 [DOI  PMID]

Sartore-Bianchi A, Pietrantonio F, Amatu A, Milione M, Cassingena A, Ghezzi S, Caporale M, Berenato R, Falcomata C, Pellegrinelli A, Bardelli A, Nichelatti M, Tosi F, De Braud F, Di Nicolantonio F, Barault L, Siena S. (2017) Digital PCR assessment of MGMT promoter methylation coupled with reduced protein expression optimises prediction of response to alkylating agents in metastatic colorectal cancer patients. European journal of cancer (Oxford, England : 1990) 71 43-50 [DOI  PMID]

Comunanza V, Cora D, Orso F, Consonni FM, Middonti E, Di Nicolantonio F, Buzdin A, Sica A, Medico E, Sangiolo D, Taverna D, Bussolino F. (2017) VEGF blockade enhances the antitumor effect of BRAFV600E inhibition. EMBO molecular medicine 9(2) 219-237 [DOI  PMID]

Van Emburgh BO, Arena S, Siravegna G, Lazzari L, Crisafulli G, Corti G, Mussolin B, Baldi F, Buscarino M, Bartolini A, Valtorta E, Vidal J, Bellosillo B, Germano G, Pietrantonio F, Ponzetti A, Albanell J, Siena S, Sartore-Bianchi A, Di Nicolantonio F, Montagut C, Bardelli A. (2016) Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer. Nature communications 7 13665 [DOI  PMID]

Picco G, Petti C, Sassi F, Grillone K, Migliardi G, Rossi T, Isella C, Di Nicolantonio F, Sarotto I, Sapino A, Bardelli A, Trusolino L, Bertotti A, Medico E. (2017) Efficacy of NEDD8 Pathway Inhibition in Preclinical Models of Poorly Differentiated, Clinically Aggressive Colorectal Cancer. Journal of the National Cancer Institute 109(2) [DOI  PMID]

Pietrantonio F, Oddo D, Gloghini A, Valtorta E, Berenato R, Barault L, Caporale M, Busico A, Morano F, Gualeni AV, Alessi A, Siravegna G, Perrone F, Di Bartolomeo M, Bardelli A, de Braud F, Di Nicolantonio F. (2016) MET-Driven Resistance to Dual EGFR and BRAF Blockade May Be Overcome by Switching from EGFR to MET Inhibition in BRAF-Mutated Colorectal Cancer. Cancer discovery 6(9) 963-71 [DOI  PMID]

Oddo D, Sennott EM, Barault L, Valtorta E, Arena S, Cassingena A, Filiciotto G, Marzolla G, Elez E, van Geel RM, Bartolini A, Crisafulli G, Boscaro V, Godfrey JT, Buscarino M, Cancelliere C, Linnebacher M, Corti G, Truini M, Siravegna G, Grasselli J, Gallicchio M, Bernards R, Schellens JH, Tabernero J, Engelman JA, Sartore-Bianchi A, Bardelli A, Siena S, Corcoran RB, Di Nicolantonio F. (2016) Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer. Cancer research 76(15) 4504-15 [DOI  PMID]

Piro G, Carbone C, Cataldo I, Di Nicolantonio F, Giacopuzzi S, Aprile G, Simionato F, Boschi F, Zanotto M, Mina MM, Santoro R, Merz V, Sbarbati A, de Manzoni G, Scarpa A, Tortora G, Melisi D. (2016) An FGFR3 Autocrine Loop Sustains Acquired Resistance to Trastuzumab in Gastric Cancer Patients. Clinical cancer research : an official journal of the American Association for Cancer Research 22(24) 6164-6175 [DOI  PMID]

Bartolini A, Cardaci S, Lamba S, Oddo D, Marchio C, Cassoni P, Amoreo CA, Corti G, Testori A, Bussolino F, Pasqualini R, Arap W, Cora D, Di Nicolantonio F, Marchio S. (2016) BCAM and LAMA5 Mediate the Recognition between Tumor Cells and the Endothelium in the Metastatic Spreading of KRAS-Mutant Colorectal Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 22(19) 4923-4933 [DOI  PMID]

Vecchione L, Gambino V, Raaijmakers J, Schlicker A, Fumagalli A, Russo M, Villanueva A, Beerling E, Bartolini A, Mollevi DG, El-Murr N, Chiron M, Calvet L, Nicolazzi C, Combeau C, Henry C, Simon IM, Tian S, in 't Veld S, D'ario G, Mainardi S, Beijersbergen RL, Lieftink C, Linn S, Rumpf-Kienzl C, Delorenzi M, Wessels L, Salazar R, Di Nicolantonio F, Bardelli A, van Rheenen J, Medema RH, Tejpar S, Bernards R. (2016) A Vulnerability of a Subset of Colon Cancers with Potential Clinical Utility. Cell 165(2) 317-30 [DOI  PMID]

Amatu A, Barault L, Moutinho C, Cassingena A, Bencardino K, Ghezzi S, Palmeri L, Bonazzina E, Tosi F, Ricotta R, Cipani T, Crivori P, Gatto R, Chirico G, Marrapese G, Truini M, Bardelli A, Esteller M, Di Nicolantonio F, Sartore-Bianchi A, Siena S. (2016) Tumor MGMT promoter hypermethylation changes over time limit temozolomide efficacy in a phase II trial for metastatic colorectal cancer. Annals of oncology : official journal of the European Society for Medical Oncology 27(6) 1062-1067 [DOI  PMID]

Arena S, Siravegna G, Mussolin B, Kearns JD, Wolf BB, Misale S, Lazzari L, Bertotti A, Trusolino L, Adjei AA, Montagut C, Di Nicolantonio F, Nering R, Bardelli A. (2016) MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations. Science translational medicine 8(324) 324ra14 [DOI  PMID]

Righi L, Vatrano S, Di Nicolantonio F, Massa F, Rossi G, Cavazza A, Volante M, Votta A, Izzo S, Lo Iacono M, Ardissone F, Di Maio M, Novello S, Scagliotti GV, Papotti M. (2016) Retrospective Multicenter Study Investigating the Role of Targeted Next-Generation Sequencing of Selected Cancer Genes in Mucinous Adenocarcinoma of the Lung. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 11(4) 504-15 [DOI  PMID]

Russo M, Siravegna G, Blaszkowsky LS, Corti G, Crisafulli G, Ahronian LG, Mussolin B, Kwak EL, Buscarino M, Lazzari L, Valtorta E, Truini M, Jessop NA, Robinson HE, Hong TS, Mino-Kenudson M, Di Nicolantonio F, Thabet A, Sartore-Bianchi A, Siena S, Iafrate AJ, Bardelli A, Corcoran RB. (2016) Tumor Heterogeneity and Lesion-Specific Response to Targeted Therapy in Colorectal Cancer. Cancer discovery 6(2) 147-153 [DOI  PMID]

Russo M, Misale S, Wei G, Siravegna G, Crisafulli G, Lazzari L, Corti G, Rospo G, Novara L, Mussolin B, Bartolini A, Cam N, Patel R, Yan S, Shoemaker R, Wild R, Di Nicolantonio F, Bianchi AS, Li G, Siena S, Bardelli A. (2016) Acquired Resistance to the TRK Inhibitor Entrectinib in Colorectal Cancer. Cancer discovery 6(1) 36-44 [DOI  PMID]

Misale S, Bozic I, Tong J, Peraza-Penton A, Lallo A, Baldi F, Lin KH, Truini M, Trusolino L, Bertotti A, Di Nicolantonio F, Nowak MA, Zhang L, Wood KC, Bardelli A. (2015) Vertical suppression of the EGFR pathway prevents onset of resistance in colorectal cancers. Nature communications 6 8305 [DOI  PMID]

Prahallad A, Heynen GJ, Germano G, Willems SM, Evers B, Vecchione L, Gambino V, Lieftink C, Beijersbergen RL, Di Nicolantonio F, Bardelli A, Bernards R. (2015) PTPN11 Is a Central Node in Intrinsic and Acquired Resistance to Targeted Cancer Drugs. Cell reports 12(12) 1978-85 [DOI  PMID]

Siravegna G, Mussolin B, Buscarino M, Corti G, Cassingena A, Crisafulli G, Ponzetti A, Cremolini C, Amatu A, Lauricella C, Lamba S, Hobor S, Avallone A, Valtorta E, Rospo G, Medico E, Motta V, Antoniotti C, Tatangelo F, Bellosillo B, Veronese S, Budillon A, Montagut C, Racca P, Marsoni S, Falcone A, Corcoran RB, Di Nicolantonio F, Loupakis F, Siena S, Sartore-Bianchi A, Bardelli A. (2015) Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients. Nature medicine 21(7) 827 [DOI  PMID]

Barault L, Amatu A, Bleeker FE, Moutinho C, Falcomata C, Fiano V, Cassingena A, Siravegna G, Milione M, Cassoni P, De Braud F, Ruda R, Soffietti R, Venesio T, Bardelli A, Wesseling P, de Witt Hamer P, Pietrantonio F, Siena S, Esteller M, Sartore-Bianchi A, Di Nicolantonio F. (2015) Digital PCR quantification of MGMT methylation refines prediction of clinical benefit from alkylating agents in glioblastoma and metastatic colorectal cancer. Annals of oncology : official journal of the European Society for Medical Oncology 26(9) 1994-1999 [DOI  PMID]

Siravegna G, Mussolin B, Buscarino M, Corti G, Cassingena A, Crisafulli G, Ponzetti A, Cremolini C, Amatu A, Lauricella C, Lamba S, Hobor S, Avallone A, Valtorta E, Rospo G, Medico E, Motta V, Antoniotti C, Tatangelo F, Bellosillo B, Veronese S, Budillon A, Montagut C, Racca P, Marsoni S, Falcone A, Corcoran RB, Di Nicolantonio F, Loupakis F, Siena S, Sartore-Bianchi A, Bardelli A. (2015) Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients. Nature medicine 21(7) 795-801 [DOI  PMID]

Medico E, Russo M, Picco G, Cancelliere C, Valtorta E, Corti G, Buscarino M, Isella C, Lamba S, Martinoglio B, Veronese S, Siena S, Sartore-Bianchi A, Beccuti M, Mottolese M, Linnebacher M, Cordero F, Di Nicolantonio F, Bardelli A. (2015) The molecular landscape of colorectal cancer cell lines unveils clinically actionable kinase targets. Nature communications 6 7002 [DOI  PMID]

Maione F, Oliaro-Bosso S, Meda C, Di Nicolantonio F, Bussolino F, Balliano G, Viola F, Giraudo E. (2015) The cholesterol biosynthesis enzyme oxidosqualene cyclase is a new target to impair tumour angiogenesis and metastasis dissemination. Scientific reports 5 9054 [DOI  PMID]

Arena S, Bellosillo B, Siravegna G, Martinez A, Canadas I, Lazzari L, Ferruz N, Russo M, Misale S, Gonzalez I, Iglesias M, Gavilan E, Corti G, Hobor S, Crisafulli G, Salido M, Sanchez J, Dalmases A, Bellmunt J, De Fabritiis G, Rovira A, Di Nicolantonio F, Albanell J, Bardelli A, Montagut C. (2015) Emergence of Multiple EGFR Extracellular Mutations during Cetuximab Treatment in Colorectal Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 21(9) 2157-66 [DOI  PMID]

Alamo P, Gallardo A, Di Nicolantonio F, Pavon MA, Casanova I, Trias M, Mangues MA, Lopez-Pousa A, Villaverde A, Vazquez E, Bardelli A, Cespedes MV, Mangues R. (2015) Higher metastatic efficiency of KRas G12V than KRas G13D in a colorectal cancer model. FASEB journal : official publication of the Federation of American Societies for Experimental Biology 29(2) 464-76 [DOI  PMID]

Misale S, Di Nicolantonio F, Sartore-Bianchi A, Siena S, Bardelli A. (2014) Resistance to anti-EGFR therapy in colorectal cancer: from heterogeneity to convergent evolution. Cancer discovery 4(11) 1269-80 [DOI  PMID]

Lamba S, Russo M, Sun C, Lazzari L, Cancelliere C, Grernrum W, Lieftink C, Bernards R, Di Nicolantonio F, Bardelli A. (2014) RAF suppression synergizes with MEK inhibition in KRAS mutant cancer cells. Cell reports 8(5) 1475-83 [DOI  PMID]

Hobor S, Van Emburgh BO, Crowley E, Misale S, Di Nicolantonio F, Bardelli A. (2014) TGFalpha and amphiregulin paracrine network promotes resistance to EGFR blockade in colorectal cancer cells. Clinical cancer research : an official journal of the American Association for Cancer Research 20(24) 6429-38 [DOI  PMID]

Van Emburgh BO, Sartore-Bianchi A, Di Nicolantonio F, Siena S, Bardelli A. (2014) Acquired resistance to EGFR-targeted therapies in colorectal cancer. Molecular oncology 8(6) 1084-94 [DOI  PMID]

Sun C, Hobor S, Bertotti A, Zecchin D, Huang S, Galimi F, Cottino F, Prahallad A, Grernrum W, Tzani A, Schlicker A, Wessels LF, Smit EF, Thunnissen E, Halonen P, Lieftink C, Beijersbergen RL, Di Nicolantonio F, Bardelli A, Trusolino L, Bernards R. (2014) Intrinsic resistance to MEK inhibition in KRAS mutant lung and colon cancer through transcriptional induction of ERBB3. Cell reports 7(1) 86-93 [DOI  PMID]

Sun C, Wang L, Huang S, Heynen GJ, Prahallad A, Robert C, Haanen J, Blank C, Wesseling J, Willems SM, Zecchin D, Hobor S, Bajpe PK, Lieftink C, Mateus C, Vagner S, Grernrum W, Hofland I, Schlicker A, Wessels LF, Beijersbergen RL, Bardelli A, Di Nicolantonio F, Eggermont AM, Bernards R. (2014) Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma. Nature 508(7494) 118-22 [DOI  PMID]

Misale S, Arena S, Lamba S, Siravegna G, Lallo A, Hobor S, Russo M, Buscarino M, Lazzari L, Sartore-Bianchi A, Bencardino K, Amatu A, Lauricella C, Valtorta E, Siena S, Di Nicolantonio F, Bardelli A. (2014) Blockade of EGFR and MEK intercepts heterogeneous mechanisms of acquired resistance to anti-EGFR therapies in colorectal cancer. Science translational medicine 6(224) 224ra26 [DOI  PMID]

Russo M, Di Nicolantonio F, Bardelli A. (2014) Climbing RAS, the everest of oncogenes. Cancer discovery 4(1) 19-21 [DOI  PMID]

Crowley EH, Arena S, Lamba S, Di Nicolantonio F, Bardelli A. (2014) Targeted knock-in of the polymorphism rs61764370 does not affect KRAS expression but reduces let-7 levels. Human mutation 35(2) 208-14 [DOI  PMID]

Zecchin D, Boscaro V, Medico E, Barault L, Martini M, Arena S, Cancelliere C, Bartolini A, Crowley EH, Bardelli A, Gallicchio M, Di Nicolantonio F. (2013) BRAF V600E is a determinant of sensitivity to proteasome inhibitors. Molecular cancer therapeutics 12(12) 2950-61 [DOI  PMID]

Crowley E, Di Nicolantonio F, Loupakis F, Bardelli A. (2013) Liquid biopsy: monitoring cancer-genetics in the blood. Nature reviews. Clinical oncology 10(8) 472-84 [DOI  PMID]

Bardelli A, Corso S, Bertotti A, Hobor S, Valtorta E, Siravegna G, Sartore-Bianchi A, Scala E, Cassingena A, Zecchin D, Apicella M, Migliardi G, Galimi F, Lauricella C, Zanon C, Perera T, Veronese S, Corti G, Amatu A, Gambacorta M, Diaz LA Jr, Sausen M, Velculescu VE, Comoglio P, Trusolino L, Di Nicolantonio F, Giordano S, Siena S. (2013) Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer. Cancer discovery 3(6) 658-73 [DOI  PMID]

Michieli P, Di Nicolantonio F. (2013) Targeted therapies: Tivantinib--a cytotoxic drug in MET inhibitor's clothes? Nature reviews. Clinical oncology 10(7) 372-4 [DOI  PMID]

Di Nicolantonio F, Bardelli A. (2013) Mouse models of Kras-mutant colorectal cancer: valuable GEMMs for drug testing? Clinical cancer research : an official journal of the American Association for Cancer Research 19(11) 2794-6 [DOI  PMID]

Valtorta E, Misale S, Sartore-Bianchi A, Nagtegaal ID, Paraf F, Lauricella C, Dimartino V, Hobor S, Jacobs B, Ercolani C, Lamba S, Scala E, Veronese S, Laurent-Puig P, Siena S, Tejpar S, Mottolese M, Punt CJ, Gambacorta M, Bardelli A, Di Nicolantonio F. (2013) KRAS gene amplification in colorectal cancer and impact on response to EGFR-targeted therapy. International journal of cancer 133(5) 1259-65 [DOI  PMID]

Zecchin D, Arena S, Martini M, Sassi F, Pisacane A, Di Nicolantonio F, Bardelli A. (2013) Modeling tumor progression by the sequential introduction of genetic alterations into the genome of human normal cells. Human mutation 34(2) 330-7 [DOI  PMID]

Misale S, Yaeger R, Hobor S, Scala E, Janakiraman M, Liska D, Valtorta E, Schiavo R, Buscarino M, Siravegna G, Bencardino K, Cercek A, Chen CT, Veronese S, Zanon C, Sartore-Bianchi A, Gambacorta M, Gallicchio M, Vakiani E, Boscaro V, Medico E, Weiser M, Siena S, Di Nicolantonio F, Solit D, Bardelli A. (2012) Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature 486(7404) 532-6 [DOI  PMID]

Bertotti A, Migliardi G, Galimi F, Sassi F, Torti D, Isella C, Cora D, Di Nicolantonio F, Buscarino M, Petti C, Ribero D, Russolillo N, Muratore A, Massucco P, Pisacane A, Molinaro L, Valtorta E, Sartore-Bianchi A, Risio M, Capussotti L, Gambacorta M, Siena S, Medico E, Sapino A, Marsoni S, Comoglio PM, Bardelli A, Trusolino L. (2011) A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer. Cancer discovery 1(6) 508-23 [DOI  PMID]

Migliardi G, Sassi F, Torti D, Galimi F, Zanella ER, Buscarino M, Ribero D, Muratore A, Massucco P, Pisacane A, Risio M, Capussotti L, Marsoni S, Di Nicolantonio F, Bardelli A, Comoglio PM, Trusolino L, Bertotti A. (2012) Inhibition of MEK and PI3K/mTOR suppresses tumor growth but does not cause tumor regression in patient-derived xenografts of RAS-mutant colorectal carcinomas. Clinical cancer research : an official journal of the American Association for Cancer Research 18(9) 2515-25 [DOI  PMID]

Prahallad A, Sun C, Huang S, Di Nicolantonio F, Salazar R, Zecchin D, Beijersbergen RL, Bardelli A, Bernards R. (2012) Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature 483(7387) 100-3 [DOI  PMID]

Bottos A, Martini M, Di Nicolantonio F, Comunanza V, Maione F, Minassi A, Appendino G, Bussolino F, Bardelli A. (2012) Targeting oncogenic serine/threonine-protein kinase BRAF in cancer cells inhibits angiogenesis and abrogates hypoxia. Proceedings of the National Academy of Sciences of the United States of America 109(6) E353-9 [DOI  PMID]

Rosa R, Melisi D, Damiano V, Bianco R, Garofalo S, Gelardi T, Agrawal S, Di Nicolantonio F, Scarpa A, Bardelli A, Tortora G. (2011) Toll-like receptor 9 agonist IMO cooperates with cetuximab in K-ras mutant colorectal and pancreatic cancers. Clinical cancer research : an official journal of the American Association for Cancer Research 17(20) 6531-41 [DOI  PMID]

Molinari F, Felicioni L, Buscarino M, De Dosso S, Buttitta F, Malatesta S, Movilia A, Luoni M, Boldorini R, Alabiso O, Girlando S, Soini B, Spitale A, Di Nicolantonio F, Saletti P, Crippa S, Mazzucchelli L, Marchetti A, Bardelli A, Frattini M. (2011) Increased detection sensitivity for KRAS mutations enhances the prediction of anti-EGFR monoclonal antibody resistance in metastatic colorectal cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 17(14) 4901-14 [DOI  PMID]

Zecchin D, Di Nicolantonio F. (2011) Transfection and DNA-mediated gene transfer. Methods in molecular biology (Clifton, N.J.) 731 435-50 [DOI  PMID]

Sartore-Bianchi A, Bencardino K, Cassingena A, Venturini F, Funaioli C, Cipani T, Amatu A, Pietrogiovanna L, Schiavo R, Di Nicolantonio F, Artale S, Bardelli A, Siena S. (2010) Therapeutic implications of resistance to molecular therapies in metastatic colorectal cancer. Cancer treatment reviews 36 Suppl 3 S1-5 [DOI  PMID]

De Roock W, Jonker DJ, Di Nicolantonio F, Sartore-Bianchi A, Tu D, Siena S, Lamba S, Arena S, Frattini M, Piessevaux H, Van Cutsem E, O'Callaghan CJ, Khambata-Ford S, Zalcberg JR, Simes J, Karapetis CS, Bardelli A, Tejpar S. (2010) Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. JAMA 304(16) 1812-20 [DOI  PMID]

Di Nicolantonio F, Arena S, Tabernero J, Grosso S, Molinari F, Macarulla T, Russo M, Cancelliere C, Zecchin D, Mazzucchelli L, Sasazuki T, Shirasawa S, Geuna M, Frattini M, Baselga J, Gallicchio M, Biffo S, Bardelli A. (2010) Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus. The Journal of clinical investigation 120(8) 2858-66 [DOI  PMID]

Sartore-Bianchi A, Bencardino K, Di Nicolantonio F, Pozzi F, Funaioli C, Gambi V, Arena S, Martini M, Lamba S, Cassingena A, Schiavo R, Bardelli A, Siena S. (2010) Integrated molecular dissection of the epidermal growth factor receptor (EGFR) [corrected] oncogenic pathway to predict response to EGFR-targeted monoclonal antibodies in metastatic colorectal cancer. Targeted oncology 5(1) 19-28 [DOI  PMID]

Di Nicolantonio F, Arena S, Gallicchio M, Bardelli A. (2010) Isogenic mutant human cells: a new tool for personalized cancer medicine. Cell cycle (Georgetown, Tex.) 9(1) 20-1 [DOI  PMID]

Sartore-Bianchi A, Di Nicolantonio F, Nichelatti M, Molinari F, De Dosso S, Saletti P, Martini M, Cipani T, Marrapese G, Mazzucchelli L, Lamba S, Veronese S, Frattini M, Bardelli A, Siena S. (2009) Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancer. PloS one 4(10) e7287 [DOI  PMID]

Siena S, Sartore-Bianchi A, Di Nicolantonio F, Balfour J, Bardelli A. (2009) Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer. Journal of the National Cancer Institute 101(19) 1308-24 [DOI  PMID]

Palmioli A, Sacco E, Airoldi C, Di Nicolantonio F, D'Urzo A, Shirasawa S, Sasazuki T, Di Domizio A, De Gioia L, Martegani E, Bardelli A, Peri F, Vanoni M. (2009) Selective cytotoxicity of a bicyclic Ras inhibitor in cancer cells expressing K-Ras(G13D). Biochemical and biophysical research communications 386(4) 593-7 [DOI  PMID]

Sartore-Bianchi A, Martini M, Molinari F, Veronese S, Nichelatti M, Artale S, Di Nicolantonio F, Saletti P, De Dosso S, Mazzucchelli L, Frattini M, Siena S, Bardelli A. (2009) PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies. Cancer research 69(5) 1851-7 [DOI  PMID]

Di Nicolantonio F, Arena S, Gallicchio M, Zecchin D, Martini M, Flonta SE, Stella GM, Lamba S, Cancelliere C, Russo M, Geuna M, Appendino G, Fantozzi R, Medico E, Bardelli A. (2008) Replacement of normal with mutant alleles in the genome of normal human cells unveils mutation-specific drug responses. Proceedings of the National Academy of Sciences of the United States of America 105(52) 20864-9 [DOI  PMID]

Di Nicolantonio F, Martini M, Molinari F, Sartore-Bianchi A, Arena S, Saletti P, De Dosso S, Mazzucchelli L, Frattini M, Siena S, Bardelli A. (2008) Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 26(35) 5705-12 [DOI  PMID]

Benvenuti S, Sartore-Bianchi A, Di Nicolantonio F, Zanon C, Moroni M, Veronese S, Siena S, Bardelli A. (2007) Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. Cancer research 67(6) 2643-8 [DOI  PMID]

Fernando A, Glaysher S, Conroy M, Pekalski M, Smith J, Knight LA, Di Nicolantonio F, Cree IA. (2006) Effect of culture conditions on the chemosensitivity of ovarian cancer cell lines. Anti-cancer drugs 17(8) 913-9 [DOI  PMID]

Knight LA, Di Nicolantonio F, Whitehouse PA, Mercer SJ, Sharma S, Glaysher S, Hungerford JL, Hurren J, Lamont A, Cree IA. (2006) The effect of imatinib mesylate (Glivec) on human tumor-derived cells. Anti-cancer drugs 17(6) 649-55 [DOI  PMID]

Bhandari P, Bateman AC, Mehta RL, Stacey BS, Johnson P, Cree IA, Di Nicolantonio F, Patel P. (2006) Prognostic significance of cyclooxygenase-2 (COX-2) expression in patients with surgically resectable adenocarcinoma of the oesophagus. BMC cancer 6 134 [DOI  PMID]

Di Nicolantonio F, Bardelli A. (2006) Kinase mutations in cancer: chinks in the enemy's armour? Current opinion in oncology 18(1) 69-76 [DOI  PMID]

Di Nicolantonio F, Mercer SJ, Knight LA, Gabriel FG, Whitehouse PA, Sharma S, Fernando A, Glaysher S, Di Palma S, Johnson P, Somers SS, Toh S, Higgins B, Lamont A, Gulliford T, Hurren J, Yiangou C, Cree IA. (2005) Cancer cell adaptation to chemotherapy. BMC cancer 5 78 [DOI  PMID]

Moroni M, Veronese S, Benvenuti S, Marrapese G, Sartore-Bianchi A, Di Nicolantonio F, Gambacorta M, Siena S, Bardelli A. (2005) Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. The Lancet. Oncology 6(5) 279-86 [DOI  PMID]

Mercer SJ, Di Nicolantonio F, Knight LA, Gabriel FG, Whitehouse PA, Sharma S, Fernando A, Bhandari P, Somers SS, Toh SK, Cree IA. (2005) Rapid up-regulation of cyclooxygenase-2 by 5-fluorouracil in human solid tumors. Anti-cancer drugs 16(5) 495-500 [DOI  PMID]

Di Nicolantonio F, Knight LA, Whitehouse PA, Mercer SJ, Sharma S, Charlton PA, Norris D, Cree IA. (2004) The ex vivo characterization of XR5944 (MLN944) against a panel of human clinical tumor samples. Molecular cancer therapeutics 3(12) 1631-7 [PMID]

Knight LA, Di Nicolantonio F, Whitehouse P, Mercer S, Sharma S, Glaysher S, Johnson P, Cree IA. (2004) The in vitro effect of gefitinib ('Iressa') alone and in combination with cytotoxic chemotherapy on human solid tumours. BMC cancer 4 83 [DOI  PMID]

Di Nicolantonio F, Knight LA, Glaysher S, Whitehouse PA, Mercer SJ, Sharma S, Mills L, Prin A, Johnson P, Charlton PA, Norris D, Cree IA. (2004) Ex vivo reversal of chemoresistance by tariquidar (XR9576). Anti-cancer drugs 15(9) 861-9 [DOI  PMID]

Di Nicolantonio F, Knight LA, Di Palma S, Sharma S, Whitehouse PA, Mercer SJ, Charlton PA, Norris D, Cree IA. (2004) Ex vivo characterization of XR11576 (MLN576) against ovarian cancer and other solid tumors. Anti-cancer drugs 15(9) 849-60 [DOI  PMID]

Whitehouse PA, Mercer SJ, Knight LA, Di Nicolantonio F, O'Callaghan A, Cree IA. (2003) Combination chemotherapy in advanced gastrointestinal cancers: ex vivo sensitivity to gemcitabine and mitomycin C. British journal of cancer 89(12) 2299-304 [DOI  PMID]

Mercer SJ, Somers SS, Knight LA, Whitehouse PA, Sharma S, Di Nicolantonio F, Glaysher S, Toh S, Cree IA. (2003) Heterogeneity of chemosensitivity of esophageal and gastric carcinoma. Anti-cancer drugs 14(6) 397-403 [DOI  PMID]

Sharma S, Neale MH, Di Nicolantonio F, Knight LA, Whitehouse PA, Mercer SJ, Higgins BR, Lamont A, Osborne R, Hindley AC, Kurbacher CM, Cree IA. (2003) Outcome of ATP-based tumor chemosensitivity assay directed chemotherapy in heavily pre-treated recurrent ovarian carcinoma. BMC cancer 3 19 [DOI  PMID]

Whitehouse PA, Knight LA, Di Nicolantonio F, Mercer SJ, Sharma S, Cree IA. (2003) Heterogeneity of chemosensitivity of colorectal adenocarcinoma determined by a modified ex vivo ATP-tumor chemosensitivity assay (ATP-TCA). Anti-cancer drugs 14(5) 369-75 [DOI  PMID]

Edmunds SC, Cree IA, Di Nicolantonio F, Hungerford JL, Hurren JS, Kelsell DP. (2003) Absence of BRAF gene mutations in uveal melanomas in contrast to cutaneous melanomas. British journal of cancer 88(9) 1403-5 [DOI  PMID]

Schondorf T, Neumann R, Benz C, Becker M, Riffelmann M, Gohring UJ, Sartorius J, von Konig CH, Breidenbach M, Valter MM, Hoopmann M, Di Nicolantonio F, Kurbacher CM. (2003) Cisplatin, doxorubicin and paclitaxel induce mdr1 gene transcription in ovarian cancer cell lines. Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer 161 111-6 [DOI  PMID]

Di Nicolantonio F, Neale M, Onadim Z, Hungerford JL, Kingston JL, Cree IA. (2003) The chemosensitivity profile of retinoblastoma. Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer 161 73-80 [DOI  PMID]

Di Nicolantonio F, Neale MH, Knight LA, Lamont A, Skailes GE, Osborne RJ, Allerton R, Kurbacher CM, Cree IA. (2002) Use of an ATP-based chemosensitivity assay to design new combinations of high-concentration doxorubicin with other drugs for recurrent ovarian cancer. Anti-cancer drugs 13(6) 625-30 [DOI  PMID]

Cree IA, Knight L, Di Nicolantonio F, Sharma S, Gulliford T. (2002) Chemosensitization of solid tumor cells by alteration of their susceptibility to apoptosis. Current opinion in investigational drugs (London, England : 2000) 3(4) 641-7 [PMID]

Cree IA, Knight L, Di Nicolantonio F, Sharma S, Gulliford T. (2002) Chemosensitization of solid tumors by modulation of resistance mechanisms. Current opinion in investigational drugs (London, England : 2000) 3(4) 634-40 [PMID]

Cantoni L, Di Nicolantonio F, Barelli D, Rizzardini M, De Matteis F. (2001) Modulation of cerebellar and hepatic nitric oxide synthase by exogenous arginine and endotoxin. Nitric oxide : biology and chemistry 5(2) 198-207 [DOI  PMID]

Courses

• Biochimica (SCB0036D)
  Laurea in Tecnica della Riabilitazione Psichiatrica
• Biochimica d'organo II (canale D) (SME1332F)
  Laurea Magistrale in Medicina e Chirurgia - sede di Torino
• Biochimica d'organo I (canale D) (SME1332D)
  Laurea Magistrale in Medicina e Chirurgia - sede di Torino
• Biochimica e biologia (canale D) (SME1332)
  Laurea Magistrale in Medicina e Chirurgia - sede di Torino
• Biochimica metabolica (canale D) (SME1332B)
  Laurea Magistrale in Medicina e Chirurgia - sede di Torino
• Chimica e propedeutica biochimica (Semestre aperto) (SME1331)
  Laurea Magistrale in Medicina e Chirurgia - sede di Torino
• Chimica e propedeutica biochimica (Semestre aperto) (SVE0371)
  Laurea Magistrale a Ciclo Unico in Medicina Veterinaria
• Epigenetica applicata alla diagnosi e terapia della patologie neoplastiche. Responsabile prof Federica Dinicolantonio
  Programma MD-PhD della Scuola di Medicina
• Scienze propedeutiche e biomediche (SCB0036)
  Laurea in Tecnica della Riabilitazione Psichiatrica
• TIROCINIO di BIOLOGIA MOLECOLARE CLINICA (SME0870)
  Corso di Laurea Magistrale in Biotecnologie Mediche - Classe LM-9

Research topics

Research topic

Our current research interests intersect epigenetics, tumor genomics, and precision oncology for hard-to-treat solid tumors, including metastatic colorectal cancer, pleural mesothelioma and pancreatic cancer.

Background

My research interests have always been inspired by the observation that the ‘one-size-fits-all’ approach should not be applied to treat cancers of the same histological type; since tumors affecting the same tissue often display individual and peculiar morphological and molecular features. My studies on the molecular mechanisms of cell transformation have been consistently aimed at identifying individualized targets amenable for therapeutic intervention as well as cancer prognostic and/or predictive biomarkers. Throughout my career, I have shown that it is possible to deliver precision cancer medicine by coupling tumor molecular profiling with functional studies in clinically relevant preclinical models.

Research achievements

Throughout my career I have demonstrated an established record of accomplishments in the field of translational oncology.

I contributed to establish that activated RAS-BRAF signaling can by-pass EGFR targeted inhibition in metastatic colorectal cancer, a notion that led to restricting the use of EGFR targeted monoclonal antibodies to RAS wild-type metastatic colorectal cancer patients. In this regard, I am the leading author of a highly cited manuscript that first described BRAF V600E mutations as a biomarker of adverse prognosis and of resistance to EGFR targeted therapies in metastatic colorectal cancer patients.

In the same field, I contributed as a co-first author to the discovery that lack of efficacy of BRAF inhibitors could be mediated by feedback re-activation EGFR in colon tumors, and proved that combinations of EGFR and BRAF inhibitors were effective in restraining growth of BRAF mutant colorectal cancer xenografts. Importantly, my preclinical works have also provided the rationale for the design of clinical trials testing BRAF and EGFR inhibitor combinations in BRAF mutant metastatic colorectal cancer patients, a regimen that is now clinically approved. My laboratory has then further shown that it possible to individualize treatment of BRAF mutant metastatic colorectal cancer patients, by studying mechanisms of primary and acquired resistance to molecularly targeted agents in tumor samples as well as in liquid biopsies.

Finally, we have developed an interest in epigenetics of colorectal cancer, since methylation changes can serve as tumor-specific changes for monitoring tumor burden in plasma circulating tumor DNA, as well as modifiers of drug response. In this regard, my team has implemented a digital PCR based assay to provide a quantitative assessment of MGMT methylation in tissue and liquid biopsies for prediction of response to alkylating agents in advanced CRC patients. Along this research topic, we have also completed genome-wide assessment of DNA methylation of a collection of over 200 colorectal cancer cell lines and compared it to normal mucosa and blood cells, in order to define a highly specific and sensitive gene methylation signature to be employed in liquid biopsy tests. We have evidence that assessment of methylated markers in cell-free circulating DNA allows non-invasive monitoring of disease burden in metastatic colorectal cancer patients. Methylation changes over time correlate with tumor response evaluated by CT-scan in patients treated with chemotherapy or targeted agents

Conclusions and perspectives

Current research projects are investigating:

The molecular bases of liquid biopsy tests for precision oncology.

The interplay between metabolism/microenvironment and epigenetics in colorectal, pancreatic and gastric cancers;

Tumor evolution under therapy;

Publications

At this link, you can find all the scientific publications of the Principal Investigator.

Activities in agenda

See my calendar

Academic bodies

• Department Council - Department of Oncology
• Departmental Board

• Collegio Docenti

Office hours

Su appuntamento da richiedere via e-mail.